ANTX vs INSM
ANTX: AN2 Therapeutics leverages a proprietary boron chemistry platform to develop small-molecule drugs for neglected infectious diseases, blood cancers, and other high-unmet-need conditions. INSM: A biopharmaceutical company with approved rare respiratory therapies (ARIKAYCE for MAC lung disease, BRINSUPRI for bronchiectasis) and a pipeline in respiratory, immunology, and neurological rare diseases.
Side-by-side fundamentals
| Metric | ANTX | INSM | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $4.89 | $106.64 | |
| Market cap as of 2026-07-23 | $176M | $23.4B | |
| Net margin as of 2026-07-23 | n/a | -144.4% | |
| Gross margin as of 2026-07-23 | n/a | +81.8% | |
| Operating margin as of 2026-07-23 | n/a | -140.6% | |
| ROE as of 2026-07-23 | -52.3% | -130.1% | ANTX higher |
| ROA as of 2026-07-23 | -47.3% | -51.6% | ANTX higher |
| Debt / equity as of 2026-07-23 | 0.00 | 1.03 | ANTX lower |
| Revenue growth (YoY) as of 2026-07-23 | n/a | +115.1% | |
| Revenue CAGR (3y) SEC XBRL | n/a | +35.2% | |
| Beta as of 2026-07-23 | -1.00 | 0.80 | |
| 1-year return as of 2026-07-22 close | +342.5% | +5.7% | ANTX higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.